F
14.00
1.35 (10.67%)
| 前收盘价格 | 12.65 |
| 收盘价格 | 12.35 |
| 成交量 | 301,103 |
| 平均成交量 (3个月) | 243,221 |
| 市值 | 201,916,000 |
| 价格/销量 (P/S) | 15.80 |
| 股市价格/股市净资产 (P/B) | 3.01 |
| 52周波幅 | |
| 利润日期 | 6 May 2026 |
| 营业利益率 (TTM) | -981.18% |
| 稀释每股收益 (EPS TTM) | -9.42 |
| 总债务/股东权益 (D/E MRQ) | 32.52% |
| 流动比率 (MRQ) | 9.41 |
| 营业现金流 (OCF TTM) | -62.63 M |
| 杠杆自由现金流 (LFCF TTM) | -61.34 M |
| 资产报酬率 (ROA TTM) | -29.82% |
| 股东权益报酬率 (ROE TTM) | -60.22% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Korro Bio, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
0.7
| 分析师共识 | 3.0 |
| 内部交易活动 | 1.5 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.70 |
|
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 6.18% |
| 机构持股比例 | 104.23% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Qiming U.S. Ventures Management, Llc | 30 Sep 2025 | 368,085 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 30.00 (Piper Sandler, 114.29%) | 购买 |
| 中 | 20.50 (46.43%) | |
| 低 | 15.00 (Chardan Capital, 7.14%) | 购买 |
| 平均值 | 21.00 (50.00%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 12.50 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Clear Street | 19 Feb 2026 | 18.00 (28.57%) | 购买 | 11.70 |
| Chardan Capital | 29 Jan 2026 | 15.00 (7.14%) | 购买 | 13.31 |
| HC Wainwright & Co. | 29 Jan 2026 | 20.00 (42.86%) | 购买 | 13.31 |
| Piper Sandler | 29 Jan 2026 | 30.00 (114.29%) | 购买 | 13.31 |
| Cantor Fitzgerald | 28 Jan 2026 | 21.00 (50.00%) | 购买 | 11.69 |
| Oppenheimer | 28 Jan 2026 | 22.00 (57.14%) | 购买 | 11.69 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 11.32 | - | 520 | 5,886 |
| 累积净数量 | 520 | |||
| 累积净值 ($) | 5,886 | |||
| 累积平均购买 ($) | 11.32 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 31 Mar 2026 | 买 (+) | 520 | 11.32 | 5,886 |
| 日期 | 类型 | 细节 |
|---|---|---|
| 20 Jan 2026 | 公告 | Korro to Host Virtual Analyst Day on January 27, 2026 |
| 08 Jan 2026 | 公告 | Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合